Cost-effectiveness analysis of two dosage forms of donepezil for Alzheimer's disease
OBJECTIVE To evaluate the economics of transdermal donepezil patch(TDP)versus tablets for Alzheimer's disease(AD)from the perspective of the whole society and provide references for the relevant health decision-making.METHODS A Markov model with four states of mild,moderate,severe and death was developed on the basis of disease pro-gression.Cost-effectiveness analysis was performed.Incremental cost-effectiveness ratio(ICER)was utilized as an index for evaluating the economics of TDP as compared with tablets.And the results were analyzed for sensitivity.RESULTS ICER of TDP versus tablets was 590 606.15 yuan/QALY.It was much higher than 3 folds per capita gross domestic product(GDP)in 2022.TDP was not economical.Sensitivity analyses revealed that severe state utility value,cost of TDP and mild state utility value had the greatest impact on the results;with a willingness-to-pay threshold of 3 folds GDP per capita in 2022,the probability of TDP being economical was zero.CONCLUSION From the perspective of the whole society,TDP is not economical as com-pared with tablets for AD.
NETL
NSTL
万方数据
